1. Home
  2. YI vs RFL Comparison

YI vs RFL Comparison

Compare YI & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 111 Inc.

YI

111 Inc.

HOLD

Current Price

$7.89

Market Cap

49.0M

ML Signal

HOLD

Logo Rafael Holdings Inc. Class B

RFL

Rafael Holdings Inc. Class B

HOLD

Current Price

$1.49

Market Cap

61.1M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
YI
RFL
Founded
2010
2017
Country
China
United States
Employees
N/A
N/A
Industry
Retail-Drug Stores and Proprietary Stores
Real Estate
Sector
Consumer Staples
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
49.0M
61.1M
IPO Year
2018
2017

Fundamental Metrics

Financial Performance
Metric
YI
RFL
Price
$7.89
$1.49
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
31.5K
58.8K
Earning Date
01-01-0001
03-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
28.28
EPS
N/A
N/A
Revenue
N/A
$917,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
43.96
52 Week Low
$2.48
$1.12
52 Week High
$11.35
$3.19

Technical Indicators

Market Signals
Indicator
YI
RFL
Relative Strength Index (RSI) 62.05 76.62
Support Level $6.75 $1.41
Resistance Level $8.59 $1.60
Average True Range (ATR) 0.37 0.07
MACD -0.15 0.02
Stochastic Oscillator 57.57 75.61

Price Performance

Historical Comparison
YI
RFL

About YI 111 Inc.

111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.

About RFL Rafael Holdings Inc. Class B

Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.

Share on Social Networks: